Robert Opitz

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Randomized Controlled Trial

Top Venues

International journal of molecular sciences

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Larissa Anthofer, Philipp Gmach, Zeynep Cansu Uretmen Kagiali, Gunnar Kleinau, Jonas Rotter, Robert Opitz, Patrick Scheerer, Annette G Beck-Sickinger, Philipp Wolf, Heike Biebermann, Ingo Bechmann, Peter Kühnen, Heiko Krude, Sarah Paisdzior
Melanocortin-4 Receptor PLC Activation Is Modulated by an Interaction with the Monocarboxylate Transporter 8. International journal of molecular sciences 25 (14) (2024)
Larissa Anthofer, Philipp Gmach, Zeynep Cansu Uretmen Kagiali, Gunnar Kleinau, Jonas Rotter, Robert Opitz, Patrick Scheerer, Annette G Beck-Sickinger, Philipp Wolf, Heike Biebermann, Ingo Bechmann, Peter Kühnen, Heiko Krude, Sarah Paisdzior
Melanocortin-4 Receptor PLC Activation Is Modulated by an Interaction with the Monocarboxylate Transporter 8. International journal of molecular sciences 25 (14) (2024)
Larissa Anthofer, Philipp Gmach, Zeynep Cansu Uretmen Kagiali, Gunnar Kleinau, Jonas Rotter, Robert Opitz, Patrick Scheerer, Annette G Beck-Sickinger, Philipp Wolf, Heike Biebermann, Ingo Bechmann, Peter Kühnen, Heiko Krude, Sarah Paisdzior
Melanocortin-4 Receptor PLC Activation Is Modulated by an Interaction with the Monocarboxylate Transporter 8. International journal of molecular sciences 25 (14) (2024)
Lara Lechner, Robert Opitz, Matt J Silver, Philipp M Krabusch, Andrew M Prentice, Martha S Field, Harald Stachelscheid, Elsa Leitão, Christopher Schröder, Valeria Fernandez Vallone, Bernhard Horsthemke, Karl-Heinz Jöckel, Börge Schmidt, Markus Maria Nöthen, Per Hoffmann, Stefan Herms, Patrick W Kleyn, Matthias Megges, Ulrike Blume-Peytavi, Katja Weiss, Knut Mai, Oliver Blankenstein, Benedikt Obermayer, Susanna Wiegand, Peter Kühnen
Early-set POMC methylation variability is accompanied by increased risk for obesity and is addressable by MC4R agonist treatment. Science translational medicine 15 (705) (2023)